Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up

Hajarizadeh, 2013, Epidemiology and natural history of HCV infection, Nat Rev Gastroenterol Hepatol, 10, 553, 10.1038/nrgastro.2013.107 Maasoumy, 2012, Natural history of acute and chronic hepatitis C, Best Pract Res Clin Gastroenterol, 26, 401, 10.1016/j.bpg.2012.09.009 Simmons, 2015, Long-term treatment outcomes of patients infected with hepatitis C Virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response, Clin Infect Dis, 61, 730, 10.1093/cid/civ396 Fehily, 2019, Long-term impact of direct-acting antiviral agent therapy in HCV cirrhosis: critical review, Semin Liver Dis, 39, 341, 10.1055/s-0039-1685538 Backus, 2011, A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C, Clin Gastroenterol Hepatol, 9, 509, 10.1016/j.cgh.2011.03.004 Buti, 2005, Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C, J Hepatol, 42, 639, 10.1016/j.jhep.2004.12.031 van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001/jama.2012.144878 Foster, 2016, Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016/j.jhep.2016.01.029 Ioannou, 2019, What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?, Gastroenterology, 156, 446, 10.1053/j.gastro.2018.10.033 D’Ambrosio, 2012, A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis, Hepatology, 56, 532, 10.1002/hep.25606 Berzigotti, 2021, EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update, J Hepatol, 75, 659, 10.1016/j.jhep.2021.05.025 Pietsch, 2018, Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals, United Eur Gastroenterol J, 6, 1188, 10.1177/2050640618786067 Singh, 2018, Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 16, 10.1016/j.cgh.2017.04.038 Nahon, 2017, Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications, Gastroenterology, 152, 10.1053/j.gastro.2016.09.009 Calvaruso, 2020, Hepatic benefits of HCV cure, J Hepatol, 73, 1548, 10.1016/j.jhep.2020.08.006 Mendizabal, 2020, Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents, Clin Gastroenterol Hepatol, 18, 10.1016/j.cgh.2020.02.044 Calvaruso, 2018, Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort, Dig Liver Dis, 50, 1, 10.1016/j.dld.2018.01.005 Fattovich, 1997, Morbidity and mortality in compensated cirrhosis Type C: a retrospective follow-up study of 384 patients, Gastroenterology, 112, 463, 10.1053/gast.1997.v112.pm9024300 Wu, 2020, Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort, Chin Med J (Engl), 133 Janjua, 2017, Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada, J Hepatol, 66, 504, 10.1016/j.jhep.2016.10.028 Brown, 2000, Interferon therapy reduces the risk for hepatocellular carcinoma, Gut, 47, 610, 10.1136/gut.47.5.610 Muzica, 2020, Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end, World J Gastroenterol, 26, 6770, 10.3748/wjg.v26.i43.6770 Reig, 2016, Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy, J Hepatol, 65, 719, 10.1016/j.jhep.2016.04.008 Conti, 2016, Early occurrence and recurrence of hepatocellular carcinoma in HCV related cirrhosis treated with direct-acting antivirals, J Hepatol, 65, 727, 10.1016/j.jhep.2016.06.015 Calleja, 2017, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort, J Hepatol, 66, 1138, 10.1016/j.jhep.2017.01.028 Ravi, 2017, Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis, Gastroenterology, 152, 911, 10.1053/j.gastro.2016.12.021 Pawlotsky, 2020, EASL recommendations on treatment of hepatitis C: final update of the series, J Hepatol, 73, 1170, 10.1016/j.jhep.2020.08.018 Lin, 2020, Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma, PLoS One, 15 Singal, 2019, Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study, Gastroenterology, 156, 10.1053/j.gastro.2019.01.027 Lui, 2020, Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a metaanalysis, Ann Gastroenterol, 33, 293